MYDECINE

NeuroPharm Inc.

Integrated into the Mydecine Innovations Group, Inc Q2, 2020, NeuroPharm Inc. (NPI) is a Canadian, Veterans focused healthcare company developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations including Veterans, EMS personnel and other high-risk constituencies. Using evidence-based medicine, NPI is developing a Psilocybin Dosing Technology and, in collaboration with its strategic partners, is establishing a therapeutic Psilocybin-based treatment to tackle the unmet needs of high-risk constituents.  

The NPI team is focused on the efficient development and clinical testing of break-through Psilocybin technologies. By leveraging strategic partnerships with global military institutions underpinned by industry, academia, scientific, medical, and clinical organizations, we are poised to bring to market much needed treatments in a cost-effective manner.  NPI is deploying an intellectual property strategy through patent filings, copyrights, trademarks, and other protective measures.

NPI is building tangible, durable competitive advantages as it secures a leadership role in treating meaningful unmet needs in a large, vulnerable population base.
← Back to homepage